⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220460 | 0.93 | — | — | |
| SCHEMBL395882 | 0.79 | — | — | |
| SCHEMBL4749332 | 0.79 | — | — | |
| SCHEMBL6268922 | 0.75 | — | — | |
| SCHEMBL825913 | 0.72 | — | — | |
| SCHEMBL5101247 | 0.72 | EPHX1 (0.33) | — | |
| SCHEMBL10437298 | 0.71 | — | — | |
| SCHEMBL10737317 | 0.71 | — | — | |
| SCHEMBL4751977 | 0.70 | — | — | |
| SCHEMBL4751771 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | claimed |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | claimed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | claimed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | claimed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | claimed |
| EP-3694840-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | Hoffmann-La Roche AG (CH) | 2020-08-19 | — | — | EP | claimed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | claimed |
| CN-111247129-A | Piperazine derivatives as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2020-06-05 | — | — | CN | claimed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| WO-2019072785-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | claimed |
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | claimed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | claimed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | claimed |
| EP-1863500-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060234963-A1 | Hepatitis C therapies | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-10-19 | — | — | US | claimed |
| WO-2006104945-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-20240182463-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20050239826-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-27 | — | — | US | disclosed |